Chronic Myeloid Leukemia Clinical Trial
Official title:
A Phase II Study of BMS-354825 in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate
Verified date | April 2011 |
Source | Bristol-Myers Squibb |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this clinical research study is to learn if BMS-354825 will have activity as defined by hematologic responses in subjects with lymphoid blast phase chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia with primary or acquired resistance to imatinib mesylate.
Status | Completed |
Enrollment | 96 |
Est. completion date | December 2007 |
Est. primary completion date | December 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Subjects with Philadelphia chromosome positive (Ph+) (BCR/ABL+) lymphoid blast phase chronic myeloid leukemia whose disease has primary or acquired hematologic resistance to imatinib mesylate or who are intolerant of imatinib mesylate. - Subjects who are considered to have lymphoid blast phase CML if they meet at least one of the following criteria: *30% lymphoid blasts in peripheral blood or bone marrow. *Extramedullary infiltrates of leukemic cells (other than in spleen or liver) with peripheral blood lymphoid blast morphology. - ECOG performance status score 0-2. - Adequate hepatic function defined as: *Total bilirubin less than or equal to 2.0 times the institutional upper limit of normal; *alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 2.5 times the institutional upper limit of normal. - Adequate renal function defined as: *serum creatinine less than or equal to 1.5 times the institutional upper normal limit. - Men and women, 18 years of age or older. - Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 1 month before and at least 3 months after the study in such a manner that the risk of pregnancy is minimized. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IC/L or equivalent units of HCG) within 72 hours prior to the start of study medication. Exclusion Criteria: - WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period of at least 1 month before and for at least 3 months after completion of the study medication. - WOCBP using a prohibited contraceptive method (not applicable). - Women who are pregnant or breastfeeding. - Women with a positive pregnancy test on enrollment or prior to study drug administration. - Men whose sexual partners are WOCBP, who are unwilling or unable to use an acceptable method to avoid pregnancy of his partner for the entire study period and for at least 3 months after completion of study medication. - Subjects who are eligible and willing to undergo transplantation during the screening period. - A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy. - Demential or altered mental status that would prohibit the understanding or rendering of informed consent. - History of significant bleeding disorder unrelated to CML. - Concurrent incurable malignancy other than CML. - Evidence of organ dysfunction or digestive dysfunction that would prevent administration of study therapy. - Subjects who received any of the following: - imatinib mesylate within 7 days; - interferon or cytarabine within 14 days; - a targeted small molecule anti-cancer agent within 14 days; - any other investigational or antineoplastic agent other than hydroxyurea or anagrelide within 28 days before starting treatment with BMS-354825. - Subjects currently taking drugs that are generally accepted to have a risk of causing Torsades de Pointes. - Subjects taking medications that irreversibly inhibit platelet function. - Prior therapy with BMS-354825. - Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Argentina | Local Institution | Buenos Aires | |
Argentina | Local Institution | Cordoba | |
Australia | Local Institution | St. Leonards | New South Wales |
Austria | Local Institution | Wien | |
Belgium | Local Institution | B-Leuven | |
Belgium | Local Institution | Edegem | |
Belgium | Local Institution | Yvoir | |
Brazil | Local Institution | Campinas | |
Brazil | Local Institution | Sao Paulo | |
Canada | Local Institution | Montreal | Quebec |
Canada | Local Institution | Toronto | Ontario |
Denmark | Local Institution | Aarhus | |
Finland | Local Institution | Helsinki | |
France | Local Institution | Lille | |
France | Local Institution | Lyon Cedex 03 | |
France | Local Institution | Nantes | |
France | Local Institution | Paris | |
France | Local Institution | Pessac | |
France | Local Institution | Poitiers Cedex | |
France | Local Institution | Strasbourg Cedex | |
Germany | Local Institution | Frankfurt/Main | |
Germany | Local Institution | Hamburg | |
Germany | Local Institution | Mainz | |
Germany | Local Institution | Mannheim | |
Israel | Local Institution | Ramat-Gan | |
Italy | Local Institution | Bologna | |
Italy | Local Institution | Orbassano | |
Italy | Local Institution | Roma | |
Korea, Republic of | Local Institution | Kyunggi-Do | |
Korea, Republic of | Local Institution | Seoul | |
Netherlands | Local Institution | Nijmegen | |
Netherlands | Local Institution | Rotterdam | |
Norway | Local Institution | Trondheim | |
Peru | Local Institution | Lima | |
Sweden | Local Institution | Gothenburg | |
Sweden | Local Institution | Lund | |
Sweden | Local Institution | Stockholm | |
Sweden | Local Institution | Umea | |
Sweden | Local Institution | Uppsala | |
Switzerland | Local Institution | Basel | |
United Kingdom | Local Institution | Glasgow | Central |
United Kingdom | Local Institution | London | Greater London |
United States | Local Institution | Anaheim | California |
United States | Local Institution | Atlanta | Georgia |
United States | Local Institution | Birmingham | Alabama |
United States | Local Institution | Boston | Massachusetts |
United States | Local Institution | Chicago | Illinois |
United States | Local Institution | Hackensack | New Jersey |
United States | Local Institution | Houston | Texas |
United States | Local Institution | Jacksonville | Florida |
United States | Local Institution | Kansas City | Kansas |
United States | Local Institution | Los Angeles | California |
United States | Local Institution | Nashville | Tennessee |
United States | Local Institution | New York | New York |
United States | Local Institution | Pittsburgh | Pennsylvania |
United States | Local Institution | Portland | Oregon |
United States | Local Institution | St. Louis | Missouri |
United States | Local Institution | Stanford | California |
United States | Local Institution | Tampa | Florida |
United States | Local Institution | Vallejo | California |
Lead Sponsor | Collaborator |
---|---|
Bristol-Myers Squibb |
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Denmark, Finland, France, Germany, Israel, Italy, Korea, Republic of, Netherlands, Norway, Peru, Sweden, Switzerland, United Kingdom,
Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007 Apr 15;109(8):3207-13. Epub 2006 Dec 21. — View Citation
Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, Rege-Cambrin G, Radich J, Hochhaus A, Apanovitch AM, Gollerkeri A, Coutre S. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007 Oct 1;110(7):2309-15. Epub 2007 May 11. — View Citation
Porkka K, Koskenvesa P, Lundán T, Rimpiläinen J, Mustjoki S, Smykla R, Wild R, Luo R, Arnan M, Brethon B, Eccersley L, Hjorth-Hansen H, Höglund M, Klamova H, Knutsen H, Parikh S, Raffoux E, Gruber F, Brito-Babapulle F, Dombret H, Duarte RF, Elonen E, Paquette R, Zwaan CM, Lee FY. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008 Aug 15;112(4):1005-12. doi: 10.1182/blood-2008-02-140665. Epub 2008 May 13. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Major and overall hematologic response rates | throughout the study | No | |
Secondary | Durability of hematologic response and time to hematologic response (major and overall) | throughout the study | No | |
Secondary | Assess cytogenetic and molecular responses | throughout the study | No | |
Secondary | Measure minor hematologic response rate in the imatinib resistant group | throughout the study | No | |
Secondary | Explore the role of BCR-ABL mRNA expression and point mutations in the BCR-ABL gene | throughout the study | No | |
Secondary | Measure the heath-related QOL using FACT-G | throughout the study | No | |
Secondary | To assess safety and tolerability of dasatinib | throughout the study | Yes | |
Secondary | Population PK | first month | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Completed |
NCT02057185 -
Occupational Status and Hematological Disease
|
||
Recruiting |
NCT03326310 -
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
|
Phase 1 | |
Recruiting |
NCT04621851 -
Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation
|
||
Completed |
NCT01207440 -
Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
|
Phase 2 | |
Not yet recruiting |
NCT06409936 -
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
|
Phase 2 | |
Active, not recruiting |
NCT02917720 -
2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients
|
Phase 2 | |
Not yet recruiting |
NCT02883036 -
Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia
|
N/A | |
Withdrawn |
NCT01188889 -
RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.
|
Phase 1/Phase 2 | |
Completed |
NCT01795716 -
Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
|
Phase 1 | |
Completed |
NCT00988013 -
Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies
|
N/A | |
Approved for marketing |
NCT00905593 -
Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
|
Phase 3 | |
Terminated |
NCT00573378 -
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
|
Phase 2 | |
Terminated |
NCT00522990 -
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
|
Phase 1/Phase 2 | |
Completed |
NCT00469014 -
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
|
Phase 2 | |
Completed |
NCT00257647 -
Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML)
|
N/A | |
Unknown status |
NCT00598624 -
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)
|
Phase 2 | |
Completed |
NCT00219739 -
STI571 ProspectIve RandomIzed Trial: SPIRIT
|
Phase 3 | |
Completed |
NCT06148493 -
Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database
|
||
Completed |
NCT00375219 -
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
|
Phase 2 |